For example, in the Study 10 trial (NCT01482715 – Rucaparib in Patients With gBRCA Mutation Ovarian Cancer), 59.5% of germline BRCA1/2-mutant high grade ovarian cancer patients achieved an investigator-assessed confirmed RECIST response to rucaparib, while 40.5% of patients exhibited de novo resistance [47]. Here, BRCA1 is linked to ovarian carcinoma.